Positive topline results for faricimab for diabetic macular oedema
The YOSEMITE and RHINE RCTs (pooled n= 1,891) met their primary endpoint and showed that faricimab given every 8 weeks and at personalized dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains vs aflibercept given every 8 weeks.
Source:
Biospace Inc.
SPS commentary:
Faricimab is an investigational bispecific antibody which binds to vascular endothelial growth factor A and angiopoietin 2.